Gout
gout management hyperuricemia
gout tophi urate crystals joint
Imaging modality and technique: Gross pathology photograph of a dissected hand/phalangeal segment. The specimen shows chalky white tophi deposits (monosodium urate crystals) within the distal interphalangeal joint region and surrounding soft tissues, with visible superficial chronic inflammatory changes. The material appears friable and is characteristic of urate crystal aggregation within periarticular tissues, tendons, ligaments, and skin. The DIP joint surfaces show cartilage erosion and juxta-articular bone irregularity due to chronic inflammatory destruction. The tophi are large, with fibrous encapsulation and overlying skin thickening; in advanced disease tophi may ulcerate the overlying epidermis, discharging chalky material. The image demonstrates joint involvement commonly seen in chronic gout, though large tophaceous specimens are less common today due to modern therapy. Associated findings include synovial thickening and chronic fibrosis leading to restricted motion. The clinical history notes gouty arthritis of the great toe; the same monosodium urate deposition process may involve other joints, including fingers near the hand. This image serves educational and diagnostic documentation purposes to illustrate features of chronic tophaceous gout, including periarticular soft tissue tophi, articular cartilage erosion, juxta-articular bone destruction, and potential skin involvement. It is useful for pathology teaching, radiology correlation, and differential diagnosis discussions of gout vs CPPD.
Imaging modality: Light microscopy of a hematoxylin and eosin (H&E) stained paraffin-embedded tissue section. Primary subject: Tissue with monosodium urate (MSU) crystal deposition consistent with gouty tophus formation. Specimen: Soft tissue biopsy with periarticular involvement; center shows brownish crystalline clusters representing surviving MSU crystals, while the surrounding tissue exhibits amorphous pink to amphophilic deposits after processing. Visual features: Focal granulomatous inflammatory milieu surrounds needle-shaped crystals that are dark brown in this preparation; crystals may appear refractile and needle-like within the central cluster. In paraffin-embedded material, MSU crystals are water-soluble and commonly dissolve during aqueous processing, leaving behind eosinophilic amorphous residues; however, at very high tissue concentrations, crystals may persist, as observed in the image center. Diagnostic significance: Histologic demonstration of urate deposition confirms local gout involvement and supports differentiation from other crystal arthropathies; persistence of crystals after processing indicates high tissue urate burden and can reflect delayed or inefficient processing. Clinical correlation: Correlate with patient history of hyperuricemia or gout, joint pain, tophi formation, and responsiveness to urate-lowering therapy. Potential use cases: educational illustration of gout pathology, research on crystal-induced inflammation, and aiding differential diagnosis in soft-tissue lesions.
This clinical photograph depicts a dorsal view of the hand with visible gouty tophi over the metacarpophalangeal joints of several digits. The image documents soft tissue nodules characteristic of chronic tophaceous gout. The tophi are subcutaneous, firm masses projecting over the dorsal MCP region, with overlying skin that may appear erythematous or thinned. In advanced disease, chalky white crystalline material may be present within the nodules, reflecting monosodium urate crystal deposition. The distribution is periarticular to the finger joints and may be bilateral and progressive. Pathophysiologically, persistent hyperuricemia promotes MSU crystal deposition with a granulomatous inflammatory response, leading to nodular masses that can cause joint erosion and functional impairment. Clinically, these findings confirm chronic gout and signal high urate burden, risk of joint destruction, and possible renal involvement. This image is educational for rheumatology and dermatology, illustrating cutaneous tophi, aiding differential diagnosis from rheumatoid nodules or xanthomas, and underscoring the role of urate-lowering therapy, diet modification, and renal evaluation. Suitable for medical education, case documentation, and teaching deposition patterns of urate crystals.
Gout
Definition & Epidemiology
Pathogenesis
- Reduced excretion (most common in primary gout, ~90% of cases) - uric acid is filtered at the glomerulus and nearly completely resorbed by the proximal tubule; a small fraction is secreted distally
- Overproduction - de novo purine synthesis or disruption of the salvage pathway (e.g., partial HGPRT deficiency; complete deficiency = Lesch-Nyhan syndrome with neurologic features)
- Secondary causes: tumor lysis syndrome, chronic renal disease, thiazide diuretics, cyclosporine, obesity, hypertension, diabetes
Crystal-Induced Inflammation
Clinical Stages
| Stage | Features |
|---|---|
| Asymptomatic hyperuricemia | Elevated urate, no symptoms; may persist for 20-30 years |
| Acute intermittent gout | Sudden severe joint pain, erythema, warmth, swelling; peaks at 1-2 days, resolves within a week |
| Intercritical gout | Asymptomatic intervals between attacks |
| Chronic tophaceous gout | No pain-free intervals; tophi in soft tissues, joints, bursae |
Clinical Features
- The first metatarsophalangeal (MTP) joint is affected in ~50% of acute attacks ("podagra")
- Knee, ankle, tarsal joints, and hand are also common sites
- Usually monoarticular, but up to 20% have polyarticular involvement
- May mimic cellulitis - acute gout of the 2nd MCP joint can resemble a hand infection (see image below)
- Systemic symptoms (fever) raise concern for septic arthritis, which must be excluded
- Tophi - painless, chalky/gritty nodules of MSU crystals; found in subcutaneous tissue, bursae, joint spaces, and tendons
Diagnosis
Synovial Fluid Analysis (gold standard)
- Arthrocentesis is recommended for first presentations or when septic arthritis cannot be excluded
- MSU crystals appear needle-shaped and negatively birefringent under polarized light microscopy (yellow parallel to compensator axis)
- WBC typically >2,000 cells/µL with neutrophil predominance
Serum Uric Acid
- Largely unhelpful acutely - gouty attacks can occur with normal serum urate levels; many hyperuricemic patients are asymptomatic
- Useful for baseline and monitoring treatment response
Imaging
- Plain X-ray: In early disease, only soft tissue swelling. Chronic disease shows asymmetric, sclerotic "punched-out" periarticular erosions with overhanging edges (outside the joint capsule) - a hallmark feature
- Ultrasound:
- Acute: Fine hyperechoic foci in effusion, synovium, or on cartilage
- The "double contour sign" - hyperechoic line along articular cartilage surface (from MSU crystal deposition)
- Tophi appear as "wet clumps of sugar" - heterogeneous center with hypoechoic rim
- DECT (dual-energy CT): Can directly detect and color-code urate deposits - highly specific for gout
Management
Acute Attack
| Drug | Mechanism | Notes |
|---|---|---|
| NSAIDs (indomethacin, naproxen, ibuprofen) | COX inhibition, anti-inflammatory | First-line; avoid in PUD, GI bleeding, renal insufficiency |
| Colchicine | Inhibits microtubule formation → blocks crystal-induced inflammation | Contraindicated in renal/hepatic insufficiency; narrow therapeutic window; GI distress common |
| Corticosteroids (prednisone 40 mg/day x 5-7 days, or intra-articular) | Broad anti-inflammatory | Preferred when NSAIDs/colchicine contraindicated; intra-articular route is very effective for monoarthritis but cannot be used if septic arthritis possible |
- Important: Urate-lowering therapy already in use should be continued during an acute flare (do not start or stop it acutely, as changes in urate levels can precipitate further attacks)
- Combination therapy (e.g., intra-articular steroid + colchicine) is reasonable for severe or debilitating cases
Chronic Management (Urate-Lowering Therapy)
| Drug | Class | Target | Notes |
|---|---|---|---|
| Allopurinol | Xanthine oxidase inhibitor | Serum urate <6 mg/dL | Start at 100-200 mg/day; dose-adjust for renal function; avoid with azathioprine (or reduce aza dose by 25%) |
| Febuxostat | Non-purine xanthine oxidase inhibitor | Serum urate <6 mg/dL | No dose adjustment for renal impairment; caution in high CV-risk patients (CARES trial showed higher all-cause & CV mortality vs. allopurinol) |
| Probenecid | Uricosuric agent | Increases uric acid excretion | Avoid in renal insufficiency; increases risk of urolithiasis |
| Pegloticase | Recombinant pegylated uricase | Converts urate → allantoin (more soluble) | FDA-approved for refractory gout; limited by anti-drug antibodies causing loss of efficacy and infusion reactions |
Lifestyle Modifications
- Avoid purine-rich foods (red meat, organ meats, shellfish, anchovies)
- Reduce alcohol (especially beer)
- Maintain adequate hydration
- Weight loss and control of comorbidities (hypertension, diabetes)
- Review medications (thiazide diuretics, cyclosporine can precipitate gout)
Complications
- Joint destruction and functional impairment from chronic tophaceous gout
- Gouty nephropathy: Urate crystal deposition in the renal interstitium and tubules
- Uric acid nephrolithiasis: Radiolucent stones (do not show on plain X-ray)
- Cardiovascular associations: Gout is associated with hypertension, metabolic syndrome, and increased CV risk
Key Differentials
| Condition | Distinguishing Features |
|---|---|
| Septic arthritis | Fever, systemically ill; culture-positive synovial fluid |
| Pseudogout (CPPD) | Calcium pyrophosphate crystals; positively birefringent, rhomboid-shaped; chondrocalcinosis on X-ray |
| Cellulitis | No joint effusion; skin involvement without crystal deposition |
| Rheumatoid arthritis | Symmetric small joint disease; RF/anti-CCP positive; morning stiffness |